The B-ALL patients who showed CD25+/CD123+ expression was categorized as group 1, while those who showed single-positive expression (CD25+/CD123− or CD25−/CD123+) and double-negative expression (CD25−/CD123−) were categorized as group 2. The gene discussed is IL3RA; the disease is acute lymphoblastic leukemia.